BlackRock amends its passive ownership disclosure in Tyra Biosciences (TYRA).

Tyra Biosciences, Inc. Estimates – NASDAQ:TYRA

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value

Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell

Raymond James Updates Healthcare Top Picks for October

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Tyra shares slip as bladder cancer responses fall short of investor expectations

Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat

Tyra disappoints investors with bladder cancer data

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data

Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib